Publications by authors named "N A Ignatenko"
Article Synopsis
- - The study aimed to evaluate how the serine protease KLK6 affects colorectal cancer development in mice with a mutant tumor suppressor gene, finding that KLK6 expression increases significantly in tumors compared to normal tissue.
- - Techniques like immunohistochemistry confirmed KLK6 presence, and genetically altered mice lacking KLK6 showed smaller tumor sizes and fewer adenomas, indicating KLK6's crucial role in tumor growth.
- - The research highlights KLK6 as an important factor for intestinal tumorigenesis, suggesting it could be useful for early diagnosis of colorectal cancer.
Soft tissue tumors/sarcomas (STSs) in felines, encompassing a variety of mesenchymal tumors with similar histomorphological features, present diagnostic challenges due to their diverse cellular origins and the overlap with other tumor types such as feline sarcoid. This study aimed to delineate the clinical, histomorphological, and immunohistochemical characteristics of 34 feline facial spindle cell tumors affecting 29 cats, including testing for bovine papillomavirus type 14 (BPV14), the virus causing feline sarcoids. Only five out of 12 tumors previously diagnosed as feline sarcoids based on histomorphology were confirmed by PCR for BPV14, underscoring the importance of comprehensive diagnostic approaches to accurately distinguish between STSs and feline sarcoids.
View Article and Find Full Text PDFThe treatment of tuberculosis is still a challenging process due to the widespread of pathogen strains resistant to antibacterial drugs, as well as the undesirable effects of anti-tuberculosis therapy. Hence, the development of safe and effective new anti-antitubercular agents, in addition to suitable nanocarrier systems, has become of utmost importance and necessity. Our research aims to develop liposomal vesicles that contain newly synthesized compounds with antimycobacterial action.
View Article and Find Full Text PDFArticle Synopsis
- Hypercytokinemia, or cytokine storm, complicates treatments for viral and bacterial infections like COVID-19 and increases thrombosis risk, highlighting the need for new anticoagulants.
- Current direct anticoagulants are limited in use for COVID-19 due to safety concerns, making the discovery of dual-action drugs with antiviral or antidiabetic properties critical, especially for patients with comorbidities like hypertension or diabetes.
- Novel compounds, particularly a specific triazolo-pyrimidine, show promising anticoagulant effects, outperforming existing medications like dabigatran etexilate and are especially effective during systemic inflammation.